These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2917113)

  • 21. Preoperative determination of susceptibility to malignant hyperthermia.
    Carson JM; Van Sickels JE
    J Oral Maxillofac Surg; 1982 Jul; 40(7):432-5. PubMed ID: 6953194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inositol 1,4,5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia.
    Wappler F; Scholz J; Köchling A; Steinfath M; Krause T; Schulte am Esch J
    Br J Anaesth; 1997 May; 78(5):541-7. PubMed ID: 9175969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory.
    Weisshorn R; Wappler F; Fiege M; Gerbershagen MU; Kolodzie K; Alberts P; Horn EP; Schulte Am Esch J
    J Clin Anesth; 2004 Aug; 16(5):353-7. PubMed ID: 15374556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dominantly inherited malignant hyperthermia (MH) in the King-Denborough syndrome.
    Isaacs H; Badenhorst ME
    Muscle Nerve; 1992 Jun; 15(6):740-2. PubMed ID: 1508238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Diagnosis of susceptibility for malignant hyperthermia using in-vitro muscle contraction testing in Switzerland].
    Urwyler A; Censier K; Seeberger MD; Drewe J; Rothenbühler JM; Frei F
    Schweiz Med Wochenschr; 1991 Apr; 121(16):566-71. PubMed ID: 2042040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Muscle biopsy for diagnosis of malignant hyperthermia susceptibility in two patients with severe exercise-induced myolysis.
    Hackl W; Winkler M; Mauritz W; Sporn P; Steinbereithner K
    Br J Anaesth; 1991 Jan; 66(1):138-40. PubMed ID: 1997050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [In-vitro-effects of cocaine in skeletal muscle specimens of patients susceptible to malignant hyperthermia].
    Weisshorn R; Wappler F; Fiege M; Gerbershagen M; Schulte Am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Mar; 37(3):138-43. PubMed ID: 11889614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Malignant hyperthermia. A case with minimal manifestations].
    Benedetti A; Bresadola F; Welber D
    Minerva Anestesiol; 1989 Jun; 55(6):287-8. PubMed ID: 2615998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
    Mortier W; Breucking E
    Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The action of ketamine on muscle contractile behavior. In vitro studies on the musculature of subjects susceptible to malignant hyperthermia].
    Hackl W; Winkler M; Mauritz W; Steinbereithner K
    Anaesthesist; 1989 Dec; 38(12):681-5. PubMed ID: 2619030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical presentation of suspected malignant hyperthermia during anaesthesia in 402 probands.
    Ellis FR; Halsall PJ; Christian AS
    Anaesthesia; 1990 Oct; 45(10):838-41. PubMed ID: 2240497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining growth hormone releasing hormone-arginine and synacthen testing diminishes the cortisol response.
    Siyambalapitiya S; Ibbotson V; Doane A; Ghigo E; Campbell MJ; Ross RJ
    J Clin Endocrinol Metab; 2007 Mar; 92(3):853-6. PubMed ID: 17192289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
    Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
    Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia?
    Sagui E; Montigon C; Abriat A; Jouvion A; Duron-Martinaud S; Canini F; Zagnoli F; Bendahan D; Figarella-Branger D; Brégigeon M; Brosset C
    PLoS One; 2015; 10(8):e0135496. PubMed ID: 26258863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Are morphologic changes in skeletal muscles of patients with malignant hyperthermia diagnostically useful?].
    Anetseder M; Pohl F; Klein R; Müller R; Hoyer A; Horbaschek H; Roggendorf W; Hartung E; Roewer N
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Oct; 34(10):626-33. PubMed ID: 10548959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should malignant hyperthermia-susceptible patients undergo muscle biopsy?
    Hinkle AJ
    Anesthesiology; 1994 Mar; 80(3):708-9. PubMed ID: 8141476
    [No Abstract]   [Full Text] [Related]  

  • 37. Muscular body build and male sex are independently associated with malignant hyperthermia susceptibility.
    Butala B; Brandom B
    Can J Anaesth; 2017 Apr; 64(4):396-401. PubMed ID: 28063098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Propofol in malignant hyperthermia.
    Harrison GG
    Lancet; 1991 Feb; 337(8739):503. PubMed ID: 1671514
    [No Abstract]   [Full Text] [Related]  

  • 39. Should we use muscle biopsy to diagnose malignant hyperthermia susceptibility?
    Larach MG
    Anesthesiology; 1993 Jul; 79(1):1-4. PubMed ID: 8342796
    [No Abstract]   [Full Text] [Related]  

  • 40. [4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].
    Wappler F; Scholz J; von Richthofen V; Fiege M; Steinfath M; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Sep; 32(9):541-8. PubMed ID: 9417254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.